Literature DB >> 10447683

Inhibition of phosphatidylcholine and phosphatidylethanolamine biosynthesis in rat-2 fibroblasts by cell-permeable ceramides.

B A Bladergroen1, M Bussière, W Klein, M J Geelen, L M Van Golde, M Houweling.   

Abstract

Phospholipids and sphingolipids are important precursors of lipid-derived second messengers such as diacylglycerol and ceramide, which participate in several signal transduction pathways and in that way mediate the effects of various agonists. The cross-talk between glycerophospholipid and sphingolipid metabolism was investigated by examining the effects of cell-permeable ceramides on phosphatidylcholine (PtdCho) and phosphatidylethanolamine (PtdEtn) synthesis in Rat-2 fibroblasts. Addition of short-chain C6-ceramide to the cells resulted in a dose- and time-dependent inhibition of the CDP-pathways for PtdCho and PtdEtn synthesis. Treatment of cells for 4 h with 50 microM C6-ceramide caused an 83% and a 56% decrease in incorporation of radiolabelled choline and ethanolamine into PtdCho and PtdEtn, respectively. Exposure of the cells for longer time-periods (>/= 16 h) to 50 microM C6-ceramide resulted in apoptosis. The structural analogue dihydro-C6-ceramide did not affect PtdCho and PtdEtn synthesis. In pulse-chase experiments, radioactive choline and ethanolamine accumulated in CDP-choline and CDP-ethanolamine under the influence of C6-ceramide, suggesting that synthesis of both PtdCho and PtdEtn were inhibited at the final step in the CDP-pathways. Indeed, cholinephosphotransferase and ethanolaminephosphotransferase activities in membrane fractions from C6-ceramide-treated cells were reduced by 64% and 43%, respectively, when compared with control cells. No changes in diacylglycerol mass levels or synthesis of diacylglycerol from radiolabelled palmitate were observed. It was concluded that C6-ceramide affected glycerophospholipid synthesis predominantly by inhibition of the step in the CDP-pathways catalysed by cholinephosphotransferase and ethanolaminephosphotransferase.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447683     DOI: 10.1046/j.1432-1327.1999.00589.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

Review 1.  Ceramide: second messenger or modulator of membrane structure and dynamics?

Authors:  Wim J van Blitterswijk; Arnold H van der Luit; Robert Jan Veldman; Marcel Verheij; Jannie Borst
Journal:  Biochem J       Date:  2003-01-15       Impact factor: 3.857

Review 2.  Surfactant phospholipid metabolism.

Authors:  Marianna Agassandian; Rama K Mallampalli
Journal:  Biochim Biophys Acta       Date:  2012-09-29

3.  High-throughput metabolomics reveals dysregulation of hydrophobic metabolomes in cancer cell lines by Eleusine indica.

Authors:  Perng Yang Puah; Dexter Jiunn Herng Lee; Soo Huan Puah; Nik Amin Sahid Nik Lah; Yee Soon Ling; Siat Yee Fong
Journal:  Sci Rep       Date:  2022-06-06       Impact factor: 4.996

4.  Cross-talk between remodeling and de novo pathways maintains phospholipid balance through ubiquitination.

Authors:  Phillip L Butler; Rama K Mallampalli
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

5.  Long-chain ceramide produced in response to N-hexanoylsphingosine does not induce apoptosis in CHP-100 cells.

Authors:  Adriano Mancinetti; Sabrina Di Bartolomeo; Angelo Spinedi
Journal:  Lipids       Date:  2009-09-26       Impact factor: 1.880

6.  Effect of oral CDP-choline on visual function in young amblyopic patients.

Authors:  Michela Fresina; Anna Dickmann; Annabella Salerni; Fabio De Gregorio; Emilio C Campos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-19       Impact factor: 3.117

7.  The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth.

Authors:  Sebastian Trousil; Maciej Kaliszczak; Zachary Schug; Quang-De Nguyen; Giampaolo Tomasi; Rosy Favicchio; Diana Brickute; Robin Fortt; Frazer J Twyman; Laurence Carroll; Andrew Kalusa; Naveenan Navaratnam; Thomas Adejumo; David Carling; Eyal Gottlieb; Eric O Aboagye
Journal:  Oncotarget       Date:  2016-06-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.